Late gadolinium enhancement and outcome of cardiac resynchronization therapy in non-ischemic cardiomyopathy.

Cardiac magnetic resonance Cardiac resynchronization therapy Late gadolinium enhancement Non-ischemic cardiomyopathy Ventricular arrhythmias

Journal

International journal of cardiology
ISSN: 1874-1754
Titre abrégé: Int J Cardiol
Pays: Netherlands
ID NLM: 8200291

Informations de publication

Date de publication:
07 Oct 2024
Historique:
received: 05 06 2024
revised: 30 08 2024
accepted: 03 10 2024
medline: 10 10 2024
pubmed: 10 10 2024
entrez: 9 10 2024
Statut: aheadofprint

Résumé

It is uncertain whether CRT with defibrillator (CRTD) is superior to CRT with pacemaker (CRTP) in NICM. Patients with low arrhythmic risk and high probability of response to CRT might be ideal candidates for CRTP. We aimed to evaluate predictors of ventricular arrhythmias and of echocardiographic response to cardiac resynchronization therapy (CRT) in non-ischemic cardiomyopathy (NICM). Multicenter, retrospective observational study of NICM patients with left ventricular ejection fraction (LVEF) ≤35 %, cardiac magnetic resonance with analysis of late gadolinium enhancement (LGE) available and de-novo CRT implant. Echocardiographic response to CRT was defined as an improvement in LVEF ≥10 %. The combined arrhythmic endpoint included sustained ventricular tachycardia, appropriate ICD therapy, resuscitated cardiac arrest and sudden death. We included 167 patients, with a median follow-up of 63 months. LGE was present in 77 (46 %). Response to CRT occurred in 68 % of patients, more frequently in LGE- than in LGE+ (81 % vs 53 %, p < 0.001). Absence of LGE (OR 3.4, p = 0.002), was an independent predictor of response to CRT. The arrhythmic endpoint occurred in 19 patients (11 %). Among LGE- patients there were zero arrhythmic events as compared to a 25 % cumulative incidence in LGE+ (p < 0.001). Presence of LGE (HR 22.5, p < 0.001), was an independent predictor of the arrhythmic endpoint. Absence of LGE identifies patients at minimal arrhythmic risk and with high probability of response to CRT. Thus, they might be ideal candidates to CRT-P.

Sections du résumé

BACKGROUND BACKGROUND
It is uncertain whether CRT with defibrillator (CRTD) is superior to CRT with pacemaker (CRTP) in NICM. Patients with low arrhythmic risk and high probability of response to CRT might be ideal candidates for CRTP. We aimed to evaluate predictors of ventricular arrhythmias and of echocardiographic response to cardiac resynchronization therapy (CRT) in non-ischemic cardiomyopathy (NICM).
METHODS METHODS
Multicenter, retrospective observational study of NICM patients with left ventricular ejection fraction (LVEF) ≤35 %, cardiac magnetic resonance with analysis of late gadolinium enhancement (LGE) available and de-novo CRT implant. Echocardiographic response to CRT was defined as an improvement in LVEF ≥10 %. The combined arrhythmic endpoint included sustained ventricular tachycardia, appropriate ICD therapy, resuscitated cardiac arrest and sudden death.
RESULTS RESULTS
We included 167 patients, with a median follow-up of 63 months. LGE was present in 77 (46 %). Response to CRT occurred in 68 % of patients, more frequently in LGE- than in LGE+ (81 % vs 53 %, p < 0.001). Absence of LGE (OR 3.4, p = 0.002), was an independent predictor of response to CRT. The arrhythmic endpoint occurred in 19 patients (11 %). Among LGE- patients there were zero arrhythmic events as compared to a 25 % cumulative incidence in LGE+ (p < 0.001). Presence of LGE (HR 22.5, p < 0.001), was an independent predictor of the arrhythmic endpoint.
CONCLUSION CONCLUSIONS
Absence of LGE identifies patients at minimal arrhythmic risk and with high probability of response to CRT. Thus, they might be ideal candidates to CRT-P.

Identifiants

pubmed: 39384095
pii: S0167-5273(24)01240-3
doi: 10.1016/j.ijcard.2024.132618
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

132618

Informations de copyright

Copyright © 2024. Published by Elsevier B.V.

Auteurs

Ignasi Anguera (I)

Cardiology Department, Bellvitge University Hospital, Hospitalet de Llobregat, Barcelona, Spain; Bioheart Group, Cardiovascular, Respiratory and Systemic Diseases and cellular aging Program, Institut d'Investigació Biomèdica de Bellvitge (IDIBELL), L'Hospitalet de Llobregat, Spain.

Valentina Faga (V)

Cardiology Department, Bellvitge University Hospital, Hospitalet de Llobregat, Barcelona, Spain; Bioheart Group, Cardiovascular, Respiratory and Systemic Diseases and cellular aging Program, Institut d'Investigació Biomèdica de Bellvitge (IDIBELL), L'Hospitalet de Llobregat, Spain.

Javier Jimenez Candil (JJ)

Cardiology Department, IBSAL-Hospital Universitario, CIBER-CV, Spain; Universidad de Salamanca, Salamanca, Spain.

Zoraida Moreno Weidmann (ZM)

Hospital de la Santa Creu i Sant Pau, Barcelona, Spain.

Alba Santos Ortega (AS)

Hospital de la Vall d'Hebron, Barcelona, Spain.

Juan Jimenez Jaimez (JJ)

Hospital Virgen de las Nieves, Granada, Spain.

Julian Rodriguez García (JR)

Cardiology Department, Bellvitge University Hospital, Hospitalet de Llobregat, Barcelona, Spain; Bioheart Group, Cardiovascular, Respiratory and Systemic Diseases and cellular aging Program, Institut d'Investigació Biomèdica de Bellvitge (IDIBELL), L'Hospitalet de Llobregat, Spain.

Eduard Claver (E)

Cardiology Department, Bellvitge University Hospital, Hospitalet de Llobregat, Barcelona, Spain; Bioheart Group, Cardiovascular, Respiratory and Systemic Diseases and cellular aging Program, Institut d'Investigació Biomèdica de Bellvitge (IDIBELL), L'Hospitalet de Llobregat, Spain.

Jordi Mercé (J)

Cardiology Department, Bellvitge University Hospital, Hospitalet de Llobregat, Barcelona, Spain; Bioheart Group, Cardiovascular, Respiratory and Systemic Diseases and cellular aging Program, Institut d'Investigació Biomèdica de Bellvitge (IDIBELL), L'Hospitalet de Llobregat, Spain.

Silvia Jovells-Vaque (S)

Bioheart Group, Cardiovascular, Respiratory and Systemic Diseases and cellular aging Program, Institut d'Investigació Biomèdica de Bellvitge (IDIBELL), L'Hospitalet de Llobregat, Spain.

Carles Diez Lopez (CD)

Cardiology Department, Bellvitge University Hospital, Hospitalet de Llobregat, Barcelona, Spain; Bioheart Group, Cardiovascular, Respiratory and Systemic Diseases and cellular aging Program, Institut d'Investigació Biomèdica de Bellvitge (IDIBELL), L'Hospitalet de Llobregat, Spain.

Jesús Hernández (J)

Cardiology Department, IBSAL-Hospital Universitario, CIBER-CV, Spain.

Nuria Rivas Gandara (NR)

Hospital de la Vall d'Hebron, Barcelona, Spain.

Rosa Macías (R)

Hospital Virgen de las Nieves, Granada, Spain.

Danae García Cosculluela (DG)

Hospital de la Santa Creu i Sant Pau, Barcelona, Spain.

Josep Comin-Colet (J)

Cardiology Department, Bellvitge University Hospital, Hospitalet de Llobregat, Barcelona, Spain; Bioheart Group, Cardiovascular, Respiratory and Systemic Diseases and cellular aging Program, Institut d'Investigació Biomèdica de Bellvitge (IDIBELL), L'Hospitalet de Llobregat, Spain; Innovation, Research and Universities Department, Gerència Territorial Metropolitana Sud, Institut Català de la Salut, Spain; Department of Clinical Sciences, School of Medicine, University of Barcelona, Spain; Centro de Investigación Biomédica en Red de Enfermedades Cardiovasculares, CIBER-CV, Madrid, Spain.

Andrea Di Marco (A)

Cardiology Department, Bellvitge University Hospital, Hospitalet de Llobregat, Barcelona, Spain; Bioheart Group, Cardiovascular, Respiratory and Systemic Diseases and cellular aging Program, Institut d'Investigació Biomèdica de Bellvitge (IDIBELL), L'Hospitalet de Llobregat, Spain. Electronic address: adimarco@bellvitgehospital.cat.

Classifications MeSH